TransMedics Group, Inc.

TransMedics develops and commercializes the Organ Care System (OCS), a portable perfusion and monitoring platform designed to preserve donor organs outside the human body under conditions that approximate physiologic function. The company's technology addresses a critical limitation in transplantation: the narrow window for organ preservation using traditional cold storage methods. By maintaining organs in a perfused, beating state during transportation and assessment, the OCS platform aims to expand the pool of viable donor organs and improve transplant outcomes.

The company offers three organ-specific OCS variants. OCS Lung preserves standard criteria donor lungs for double-lung transplantation. OCS Heart preserves hearts deemed unsuitable for transplantation under conventional cold storage, including hearts from donation-after-circulatory-death donors. OCS Liver preserves both donation-after-brain-death and donation-after-circulatory-death donor livers. TransMedics also provides complementary services including a national organ retrieval program, organ management logistics, aviation and ground transportation coordination, and related support services.

The company operates with approximately 900 full-time employees and maintains headquarters in Andover, Massachusetts. TransMedics markets its products internationally, with established commercial presence in the United States and expanding operations in select international markets.